Figure 3 from MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5
Year: 2026
Type: other
Abstract: Steatohepatitis in nontumor regions of DEN-treated WT and miR-146a−/− female mouse livers. A, WT mouse liver, showing no significant steatosis, hypertrophy, or inflammation. B,miR-146a−/− liver, showing macrovesicular steatosis (arrows) and zones of microvesicular steatosis and hypertrophy (lower right of dashed line). C, WT mouse liver, showing a central vein with surrounding unremarkable hepatocytes. D,miR-146a−/− genotype, showing two clusters of inflammatory cells (circled) and hypertrophy. Some hypertrophied hepatocytes contain microvesicular steatosis (arrowheads), whereas others have rarified cytoplasm and Mallory–Denk bodies similar to ballooned hepatocytes in human patients (arrow). H&E stains. Scale bars are 40 μm. A and B, Magnification 20×. C and D, Magnification 40×. E, Non-alcoholic fatty liver disease activity scores (NAS). Scores were calculated on a nine-point scale with the nine points being derived from a sum of these measurements: hepatocyte hypertrophy, inflammation, and steatosis using an established scoring system (52). F, Inflammation score (Fisher’s exact test, separated between 0–2 and 3). G, Fat cores: 0 ≤ 5% fat; 1 = 5%–33% fat; 2 = 33%–66% fat; 3 ≥ 66% fat. H, Hypertrophy score (Fisher’s exact test, separated between 0–2 and 3). The data represent three experiments. Bar chart (E) displays points representing individual mice and error bars representing mean ± SEM. *, P < 0.05; **, P < 0.01.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7130649459